Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | WDR5 | P61964 | 8/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.33 |
| ▸ | SMO | Q99835 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.33 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL784592 | 0.91 | WDR5 (0.36) | WDR5HCRTR1HCRTR2SMOKLKB1 | |
| SCHEMBL785366 | 0.90 | WDR5 (0.38) | WDR5HCRTR1HCRTR2SMOKLKB1 | |
| SCHEMBL784457 | 0.90 | WDR5 (0.36) | WDR5HCRTR1HCRTR2SMOKLKB1 | |
| SCHEMBL785260 | 0.88 | WDR5 (0.35) | WDR5HCRTR1HCRTR2SMOKLKB1 | |
| SCHEMBL784313 | 0.88 | MEN1 (0.43) | PDE4APDE4BPDE4CPDE4DWDR5 | |
| SCHEMBL784608 | 0.88 | MEN1 (0.43) | PDE4APDE4BPDE4CPDE4DWDR5 | |
| SCHEMBL785506 | 0.86 | TAF1 (0.38) | WDR5HCRTR1HCRTR2SMOKLKB1 | |
| SCHEMBL785107 | 0.85 | WDR5 (0.37) | WDR5SMOPDK2ACKR3PDE10A | |
| SCHEMBL785488 | 0.85 | GBA1 (0.38) | WDR5GBA1HCRTR1HCRTR2SMO | |
| SCHEMBL784800 | 0.84 | WDR5 (0.40) | WDR5HCRTR1HCRTR2SMOPDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | claimed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | claimed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | PDE4A 944/4885PDE4B 939/4885PDE4C 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.